Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Precision Oncology in Lower-Grade Gliomas: Promises and Pitfalls of Therapeutic Strategies Targeting IDH-Mutations

22 Feb 2022

Abstract excerpt

Mutations in isocitrate dehydrogenase (IDH)1 and its homolog IDH2 are considered an earliest “driver” genetic event during gliomagenesis, representing now the molecular hallmark of lower-grade gliomas (LGGs). IDH-mutated genes encode for a neomorphic enzyme that converts α-ketoglutarate to the oncometabolite D-2-hydroxyglutarate (2-HG), which accumulates to high concentrations and alters cellular epigenetics and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer, Hypoxia, and Metabolism
Share to Glioma Diagnosis and Treatment
Share to Histone Deacetylase Inhibitors Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 35267433
DOI: 10.3390/cancers14051125

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Precision Oncology in Lower-Grade Gliomas: Promises and Pitfalls of Therapeutic Strategies Targeting IDH-MutationsPMID 35267433Read ↗

IDH Mutations in Glioma: Double-Edged Sword in Clinical Applications?Semantic proximity Read ↗

Molecular biology and novel therapeutics for IDH mutant gliomas: The new era of IDH inhibitors.Semantic proximity Read ↗

IDH Inhibitors and Beyond: The Cornerstone of Targeted Glioma Treatment.Semantic proximity Read ↗

Isocitrate dehydrogenase mutation as a therapeutic target in gliomas.Semantic proximity Read ↗

Bridging Cancer Biology with the Clinic: Comprehending and Exploiting IDH Gene Mutations in Gliomas.Semantic proximity Read ↗

Therapies for IDH-Mutant Gliomas.Semantic proximity Read ↗

Isocitrate Dehydrogenase Mutations in Glioma: Genetics, Biochemistry, and Clinical IndicationsSemantic proximity Read ↗

Isocitrate dehydrogenase 1 and 2 mutations in gliomas.Semantic proximity Read ↗

Isocitrate dehydrogenase mutations in gliomas.Semantic proximity Read ↗

Beyond Brooding on Oncometabolic Havoc in IDH-Mutant Gliomas and AML: Current and Future Therapeutic StrategiesSemantic proximity Read ↗

Biological Significance of Mutant Isocitrate Dehydrogenase 1 and 2 in Gliomagenesis.Semantic proximity Read ↗

Isocitrate Dehydrogenase Mutations in Glioma: From Basic Discovery to Therapeutics DevelopmentSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.